|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
ASCVD Risk Panel with Score
Test Code92053
CPT Codes
82465, 83718, 84478<br>Note: Coding may vary depending on health plan or government payer requirements. CMS does not currently recognize MAAA CPT codes for Medicare claims.
Includes
Cholesterol, Total; HDL Cholesterol; Triglycerides; Non-HDL and Calculated Components; Cholesterol, Direct LDL; ASCVD Risk Scores
If Triglyceride is >400 mg/dL, Direct LDL will be performed at an additional charge (CPT code(s): 83721).
If Triglyceride is >400 mg/dL, Direct LDL will be performed at an additional charge (CPT code(s): 83721).
Preferred Specimen
2 mL serum
Patient Preparation
See individual assays
Triglyceride test only: Patient should fast 9-12 hours prior to collection.
As part of lipid panel testing: A fasting sample is not required.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol, uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
Minimum Volume
1 mL
Other Acceptable Specimens
Plasma collected in a sodium heparin or sodium lithium (green-top) tube
Instructions
For risk calculations to be performed, the following patient specific information have to be provided at time
of order:
Age: Years
Gender: M (for male) or F (for female)
Race-African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for Yes) or N (for no)
of order:
Age: Years
Gender: M (for male) or F (for female)
Race-African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for Yes) or N (for no)
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 28 days
Refrigerated: 7 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Moderate to gross icterus • Anticoagulants other than heparin
Methodology
Enzymatic • Spectrophotometry (SP)
Setup Schedule
Monday-Friday All Shifts Saturday Morning Sunday Morning, Night Report available: Next Day
Reference Range
Total Cholesterol |
Male (mg/dL) |
Female (mg/dL) |
<20 Years | <170 | <170 |
≥20 Years | <200 | <200 |
HDL Cholesterol | ||
<20 Years | >45 | >45 |
≥20 Years | ≥40 | ≥50 |
Triglycerides | ||
≤9 Years | <75 | <75 |
10-19 Years | <90 | <90 |
≥20 Years | <150 | <150 |
LDL-Cholesterol (Calc) | ||
<20 Years | <110 | <110 |
≥20 Years | <100 | <100 |
Cholesterol/HDL Ratio (Calc) | <5.0 | <5.0 |
Non-HDL Cholesterol | ||
<20 Years | <120 | <120 |
≥20 Years | <130 | <130 |
ASCVD Risk Scores | See Laboratory Report |
Clinical Significance
This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history.
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.